Oryzon Genomics is a Spanish biotech focused on epigenetics. Iadademstat (Phase IIa) is being explored for acute leukaemias and SCLC; vafidemstat, its CNS product, has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder is ongoing. ORY-3001 is being developed for certain orphan indications.
Oryzon develops small molecule inhibitors for epigenetic targets. It has completed five Phase II and has three ongoing Phase II trials with two assets iadademstat (a specific LSD1 inhibitor) and vafidemstat (a CNS-optimised LSD1 inhibitor). Oryzon reported data in March 2021 from its two Phase IIa trials focusing on AD (ETHERAL and REIMAGINE-AD). Vafidemstat was confirmed to be safe and was effective in controlling aggression and agitation, which is a key focus area for Oryzon. To this end, in July 2020 results from the Phase IIa REIMAGINE trial with vafidemstat for aggressiveness in psychiatric diseases showed improvement in all cohorts (BPD, ADHD and ASD). Oryzon has enrolled the first BPD patient in the Phase IIb PORTICO trial for vafidemstat and also announced a new trial for schizophrenia (EVOLUTION). In December 2020, Oryzon presented more data from the Phase II ALICE trial (iadademstat plus azacitidine) in AML, which continues to impress, and has been granted Orphan Drug Designation.
Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and potentially a favourable safety/efficacy profile than the first generation HDAC inhibitors.